All In Biotech

Drug Trial Radar · NCT01808092

A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia

A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults

Last checked: Nov 19, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 969 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

969

Actual

Start

Apr 2013

Primary completion

Jan 2016

Study completion Jan 2016

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the effects of Ceftazidime-Avibactam compared to Meropenem for treating hospitalized adults with nosocomial pneumonia including ventilator-associated pneumonia

Conditions

  • Nosocomial Pneumonia (NP)
  • Ventilator-associated Pneumonia (VAP)

Interventions

  • ceftazidim-avibactam (CAZ-AVI, experimental product)Drug

    2000mg ceftazidime plus 500mg avibactam

  • meropenem (active comparator)Drug

    1000mg of Meropenem

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses)Time frame: At the test-of-cure (TOC) visit (Day 21 to 25)
  2. The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Evaluable at TOC Analysis Set (Co-primary Analyses)Time frame: At the test-of-cure (TOC) visit (Day 21 to 25)

Locations

123 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    Florida, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Mendoza, Argentina

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Campinas/SP, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    Burgas, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Rousse, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Guangzhou, China

  • Research Site

    Haikou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Jiangyin, China

  • Research Site

    Nanchang, China

  • Research Site

    Qingdao, China

  • Research Site

    Sanya, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Shenzhen, China

  • Research Site

    Suzhou, China

  • Research Site

    Tianjin, China

  • Research Site

    Xi'an, China

  • Research Site

    Xiamen, China

  • Research Site

    Yangzhou, China

  • Research Site

    Zhanjiang, China

  • Research Site

    Kolín, Czechia

  • Research Site

    Kyjov, Czechia

  • Research Site

    Praha 10, Prague, Czechia

  • Research Site

    Limoges, France

  • Research Site

    Nantes, France

  • Research Site

    Paris, France

  • Research Site

    Pierre-Bénite, France

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.